Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.

A review of the literature on MDMA-assisted psychotherapy for PTSD describes the drug's history, proposed mechanism, and potential risks. Across six phase two trials involving 105 blinded participants with chronic PTSD, the overall remission rate was 66.2% with low rates of adverse effects. The evidence suggests MDMA can be a safe and effective adjunct to psychotherapy, though more research is needed to confirm its therapeutic role.

Study at a glance

Abstract

The present paper discusses the current literature with regard to substance-assisted psychotherapy with Methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder (PTSD). The aim of the paper is to give a comprehensive overview of the development from MDMA's early application in psychotherapy to its present and future role in the treatment of PTSD. It is further attempted to increase the attention for MDMA's therapeutic potential by providing a thorough depiction of the scientific evidence regarding its theorized mechanism of action and potential harms of its application in the clinical setting (e.g., misattribution of therapeutic gains to medication instead of psychological changes). Empirical support for the use of MDMA-assisted psychotherapy, including the randomized, double-blind, placebo-controlled trails that have been conducted since 2008, is discussed. Thus far, an overall remission rate of 66.2% and low rates of adverse effects have been found in the six phase two trials conducted in clinical settings with 105 blinded subjects with chronic PTSD. The results seem to support MDMA's safe and effective use as an adjunct to psychotherapy. Even though preliminary studies may look promising, more studies of its application in a psychotherapeutic context are needed in order to establish MDMA as a potential adjunct to therapy.